UroGen Pharma shares are trading higher after the company on Thursday announced an 82.3% 12-month duration of response in its Phase 3 ENVISION trial for UGN-102, achieving a 79.6% complete response rate at three months. On Friday, multiple analysts raised their price targets.
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma shares surged after announcing positive results from its Phase 3 ENVISION trial for UGN-102, with an 82.3% 12-month duration of response and a 79.6% complete response rate at three months. Analysts subsequently raised their price targets.
June 14, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma shares surged after the company announced positive results from its Phase 3 ENVISION trial for UGN-102, showing an 82.3% 12-month duration of response and a 79.6% complete response rate at three months. Multiple analysts raised their price targets following the announcement.
The positive results from the Phase 3 ENVISION trial for UGN-102 are a significant milestone for UroGen Pharma, indicating strong efficacy of the treatment. The subsequent increase in price targets by multiple analysts further supports a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100